secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123274
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026
-------------------------------------------------------------------

- Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.
- Cash, cash equivalents, and short-term investments total $167.1M as of Sept 30, 2024.
- Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP trials; initial proof-of-concept data expected H2 2025.
- Analytical validation for proprietary ecDNA diagnostic ECHO presented at ESMO September 2024.
- G&A expenses $4.6M vs $3.3M year-over-year; general operating cash runway into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/0000950170-24-123274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/bold-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer